1 Min Read
Feb 8 (Reuters) - A U.S. appeals court on Wednesday has stayed an order that would have blocked Regeneron Pharmaceuticals Inc and Sanofi SA from selling their cholesterol drug, Praluent, later this month while they appeal.
A federal judge had earlier blocked sales of the drug after rival Amgen Inc won a trial in which it accused them of infringing its patents. The order would have taken effect on Feb. 21. (Reporting by Brendan Pierson in New York; Editing by Phil Berlowitz)